PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
43.33%
Net income growth above 1.5x TRAW's 7.65%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-26.41%
Both reduce yoy D&A, with TRAW at -26.53%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-627.56%
Negative yoy deferred tax while TRAW stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
174.63%
SBC growth well above TRAW's 64.45%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-214.26%
Negative yoy working capital usage while TRAW is 158.26%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-295.13%
Negative yoy AP while TRAW is 87.48%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-30.84%
Negative yoy usage while TRAW is 346.72%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
848.72%
Well above TRAW's 100.00%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-15.17%
Negative yoy CFO while TRAW is 30.95%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth well above TRAW's 100.00%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have some outflow growth while TRAW is negative at -100.00%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
100.00%
We have mild expansions while TRAW is negative at -100.00%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-2235.51%
We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
219.76%
Issuance growth of 219.76% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.